Trial Profile
An International Multicenter Open-label Randomized Trial of the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) as Monotherapy in Patients With Unresectable/Metastatic Melanoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Malignant melanoma; Uveal melanoma
- Focus Therapeutic Use
- Acronyms MIRACULUM
- Sponsors Biocad
- 16 Apr 2021 Status changed from active, no longer recruiting to completed.
- 16 Apr 2021 Primary endpoint (Overall response rate) has been met.
- 16 Apr 2021 Results published in the European Journal of Cancer.